Risperidone Tablets, 1 mg Bioequivalence Study of Dr.Reddy’s Under Fed Condition

Overview

A Single-dose, Randomized, two-Period, Cross over Study

Full Title of Study: “A Relative Bioavailability Study of Two Risperidone 1 mg Tablet Formulations Under Fed Conditions”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2006

Detailed Description

Randomized, single-dose, two-treatment, two-way, crossover study was conducted to compare the relative bioavailability of two risperidone 1 mg tablet formulations under Fed conditions. The test formulation was Dr. Reddy's Laboratories Limited's 1 mg Risperidone tablet, and the reference formulation was Risperdal® (risperidone) 1 mg tablet (Janssen Pharmaceutica Products, L.P.). The study was conducted with 26 healthy adults. In each study period, a single 1 mg dose was administered to the subjects following a standardized high-fat breakfast preceded by an overnight fast of at least 10 hours. The subjects received the test product in one study period and the reference product in the other period; the order of administration was according to the dosing randomization schedule. There was a 7-day interval between treatments.

Interventions

  • Drug: Risperidone
    • Risperidone Tablets 1 mg

Arms, Groups and Cohorts

  • Experimental: Risperidone
    • Risperidone Tablets 1 mg of Dr Reddys Laboratories Limited
  • Active Comparator: Risperdal®
    • Risperdal® Tablets, 1 mg of Janssen Pharmaceutica Products, L.P

Clinical Trial Outcome Measures

Primary Measures

  • Bio-equivalence study of Dr Reddys Laboratories Risperidone Tablets 1 mg
    • Time Frame: 3-4 months

Participating in This Clinical Trial

Inclusion Criteria

1. Males and females, 18 – 55 years of age. 2. Female subjects of child bearing potential must either abstain from sexual intercourse or use a reliable method of contraception (e.g. condom with spermicide, IUD, hormonal contraceptives) for at least 30 days prior to dosing and during the duration of the study. 3. A body mass index (BMI) of 18-30 kg/m² inclusive as calculated according to Novum Standard Operating Procedures. 4. Good health as determined by lack of clinically significant abnormalities in health assessments performed at screening. 5. Signed and dated informed consent form, which meets all criteria of current FDA regulations. Exclusion Criteria:

1. If female, pregnant, lactating or likely to become pregnant during the study. 2. History of allergy or sensitivity to risperidone, or similar drugs, or history of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the study. 3. Significant history or current evidence of chronic infectious disease, system disorder or organ dysfunction. 4. Presence of gastrointestinal disease or history of malabsorption within the last year. 5. History of psychiatric disorders occurring within the last two years that required hospitalization or medication. 6. Presence of a medical condition requiring regular treatment with prescription drugs. 7. Use of pharmacologic agents known to significantly induce or inhibit drug-metabolizing enzymes within 30 days prior to initial dosing. 8. Receipt of any drug as part of a research study within 30 days prior to dosing. 9. Drug or alcohol addiction requiring treatment in the past 12 months. 10. Donation or significant loss of whole blood (480 ml or more) within 30 days or plasma within 14 days prior to dosing. 11. Positive test results for HIV, Hepatitis B surface antigen, or Hepatitis C antibody. 12. Positive test results for drugs of abuse at screening. 13. Positive serum pregnancy test. 14. Subjects who smoke more than 10 cigarettes/day or equivalent tobacco use. 15. Subjects who have been on a special diet during the 28 days prior to dosing 16. Subjects who consume on average more than 3 units of alcohol/day.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Dr. Reddy’s Laboratories Limited
  • Provider of Information About this Clinical Study
    • Senior Director – Research & Development, Dr. Reddy’s Laboratories Limited
  • Overall Official(s)
    • Shirley Ann Kennedy, MD, Principal Investigator, Novum Pharmaceutical Research Services, 5900 Penn Avenue, Pittsburgh, PA 15206-3817

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.